Literature DB >> 30417352

Troxerutin attenuates myocardial cell apoptosis following myocardial ischemia-reperfusion injury through inhibition of miR-146a-5p expression.

Liliang Shu1, Wanzhe Zhang2, Gongcheng Huang1, Chen Huang1, Xiaohua Zhu1, Gang Su1, Jing Xu1.   

Abstract

The aim of the current study was to investigate the effects and the underlying mechanisms of troxerutin on myocardial cell apoptosis during ischemia-reperfusion (I/R) injury. Hypoxia/reoxygenation (H/R) model in neonatal rat cardiomyocytes, and I/R model in rats, were established following troxerutin preconditioning. The quantitative real-time polymerase chain reaction analysis was performed to examine the messenger RNA miR-146a-5p expression in cardiomyocytes and myocardial tissues. Hemodynamic parameters and serum creatine kinase, lactate dehydrogenase, tumor necrosis factor-α, and interleukin-10 were evaluated. Infarct size was examined by 2,3,5-triphenyltetrazolium chloride staining. Besides, myocardial apoptosis was detected by terminal deoxynucleotidyl transferase (dUTP) nick end labeling (TUNEL) assay. Western blot analysis was performed to determine the protein levels of caspase-3, Bax, and Bcl-2. The results showed that, troxerutin decreased rat cardiomyocyte apoptosis during H/R injury. Furthermore, the antiapoptotic effect of troxerutin against I/R injury was mediated by miR-146a-5p downregulation. In vivo experiments suggested that troxerutin alleviated myocardial I/R injury in rats via inhibition of miR-146a-5p. In conclusion, troxerutin exerted cardioprotective effects during I/R injury by downregulating miR-146a-5p.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  apoptosis; cardiomyocytes; ischemia-reperfusion; miR-146a-5p; troxerutin

Mesh:

Substances:

Year:  2018        PMID: 30417352     DOI: 10.1002/jcp.27607

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

Review 1.  MicroRNAs as Potential Pharmaco-targets in Ischemia-Reperfusion Injury Compounded by Diabetes.

Authors:  Hassan Dehaini; Hussein Awada; Ahmed El-Yazbi; Fouad A Zouein; Khodr Issa; Assaad A Eid; Maryam Ibrahim; Adnan Badran; Elias Baydoun; Gianfranco Pintus; Ali H Eid
Journal:  Cells       Date:  2019-02-12       Impact factor: 6.600

2.  Troxerutin attenuates oxygen‑glucose deprivation and reoxygenation‑induced oxidative stress and inflammation by enhancing the PI3K/AKT/HIF‑1α signaling pathway in H9C2 cardiomyocytes.

Authors:  Zhang-Ping Yu; Han-Qiao Yu; Jun Li; Chao Li; Xian Hua; Xiao-Sheng Sheng
Journal:  Mol Med Rep       Date:  2020-06-03       Impact factor: 2.952

3.  miR-146a attenuates apoptosis and modulates autophagy by targeting TAF9b/P53 pathway in doxorubicin-induced cardiotoxicity.

Authors:  Jian-An Pan; Yong Tang; Jian-Ying Yu; Hui Zhang; Jun-Feng Zhang; Chang-Qian Wang; Jun Gu
Journal:  Cell Death Dis       Date:  2019-09-11       Impact factor: 8.469

4.  Intranasal Administration of miR-146a Agomir Rescued the Pathological Process and Cognitive Impairment in an AD Mouse Model.

Authors:  Hui Mai; Weihao Fan; Yan Wang; Yujie Cai; Xiaohui Li; Feng Chen; Xiongjin Chen; Jingqi Yang; Pei Tang; Huiyi Chen; Ting Zou; Tingting Hong; Conghua Wan; Bin Zhao; Lili Cui
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-10       Impact factor: 8.886

5.  The Protective Roles and Molecular Mechanisms of Troxerutin (Vitamin P4) for the Treatment of Chronic Diseases: A Mechanistic Review.

Authors:  Mohammad Zamanian; Gholamreza Bazmandegan; Antoni Sureda; Eduardo Sobarzo-Sanchez; Hasan Yousefi-Manesh; Samira Shirooie
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

6.  Analysis of the miRNA-mRNA Regulatory Network Reveals the Biomarker Genes in the Progression of Myocardial Ischemic Reperfusion.

Authors:  Nini Li; Qing Chen
Journal:  J Healthc Eng       Date:  2022-04-13       Impact factor: 3.822

7.  MiR-199 Aggravates Doxorubicin-Induced Cardiotoxicity by Targeting TAF9b.

Authors:  Yangsheng Yu; Degang Guo; Lin Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-15       Impact factor: 2.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.